Frontiers in Lipid Biology

脂质生物学前沿

• 批准号: 8398166
• 负责人: WILLIAM DOWHAN
• 金额: $ 1.3万
• 依托单位: AMERICAN SOCIETY FOR BIOCHEMIS/ MOL BIOL
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8398166
• 关键词: Address; Alzheimer' s Disease; American; Animals; Atherosclerosis; Biochemistry; Biology; Canada; Cells; Cellular biology; Child Care; Cholesterol; Clinical; Coffee; Collaborations; Data; Development; Disease; Ethnic Origin; Europe; European; Faculty; Fatty Liver; Fatty acid glycerol esters; Future; Genetic; Health; Heart Diseases; Homeostasis; Hour; Human; Impairment; Individual; Industry; International; Knowledge; Lipids; Lipoproteins; Liver diseases; Lung diseases; Mammalian Cell; Membrane; Metabolic syndrome; Metabolism; Methodology; Molecular; Molecular Biology; Nerve Degeneration; Neurodegenerative Disorders; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Oral; Participant; Physicians; Plasma; Postdoctoral Fellow; Process; Regulation; Research; Risk; Scientist; Signal Transduction; Societies; Structural Biologist; System; Time; Triglycerides; Western World; Woman; Work; abstracting; base; disability; frontier; graduate student; human disease; lipid metabolism; lipid transport; meetings; membrane model; men; microorganism; minority trainee; novel; posters; programs; symposium

DESCRIPTION (provided by applicant): This application is for partial support of a unique international conference sponsored by the American Society of Biochemistry and Molecular Biology (ASBMB) and entitled "Frontiers in Lipid Biology". This conference will bring together scientists who will present, exchange and disseminate their research and explore possible future collaborations. The conference is jointly organized by ASBMB, the International Conference on the Bioscience of Lipids (ICBL) and the Canadian Lipoprotein Conference (CLC). The expected number of attendees is 250 to 300. The participants will include geneticists, physician scientists, molecular biologists, biochemists, cell biologists, physiologist and structural biologists, as well as scientists from industry and many trainees. The program will focus on emerging topics in lipid biology including genetic regulation of lipid metabolism, regulation of fat storage, cell biology of lipids, lipid trafficking, lipid signaling, membrane dynamics, as well as impairment of lipid homeostasis in lung disease, neurodegenerative diseases, heart disease, type 2 diabetes and obesity. The ICBL and the CLC each hold annual conferences on lipid metabolism that have been well attended for 52 and 35 years, respectively. Importantly, this year's conference is co-sponsored by the ASBMB as a "Special Symposium". Thus, this unique combined meeting will be organized by scientists based in the US, Canada and Europe, and will provide a unique opportunity to bring together lipid biologists from diverse international backgrounds. The conference will take place from Sept 5 to 9, 2012, at the Banff Centre in Banff, Canada. The conference will focus on the growing recognition that dysfunctional lipid metabolism underlies the development of many human diseases such as obesity, atherosclerosis, metabolic syndrome, liver and lung disease and neurodegenerative disorders. The program includes 7 scientific sessions that will each feature 3 or 4 talks, each 30 min long plus 10 min discussion. A special feature of this conference is the emphasis on presentations by graduate students, postdoctoral fellows and junior faculty. Internationally recognized scientists who will be selected for their scientific excellence as well as their abilityto present their work clearly and logically will give talks in each of the sessions. In addition, 3.5 hours each day will be devoted to poster presentations that will provide an excellent forum for informal discussions among trainees and established scientists. The program and the organizing committee include outstanding women and men scientists of diverse ethnicities. PUBLIC HEALTH RELEVANCE: The most prevalent human diseases in the western world are characterized by dysregulation of lipid homeostasis. For example, excess lipids that is stored as fat (triglycerides) contribute to health problems associated with obesity, fatty liver and type 2 diabetes. An excess of plasma cholesterol markedly increases the risk of atherosclerosis and has been associated with several neurodegenerative diseases such as Alzheimer disease. This unique international conference will address current issues in lipid metabolic processes and their relationship to human disease. The fundamental processes of lipid synthesis, breakdown and storage will be discussed in studies that range from basic mechanisms to clinical implications. The meeting will, therefore, bring together internationally recognized basic scientists and physician scientists to present their latest data on how impairment of lipid metabolic processes contribute to the development of disorders such as atherosclerosis, obesity, type 2 diabetes, liver and lung disease and neurodegeneration.

描述（由申请人提供）：此申请是为了部分支持美国生物化学和分子生物学学会（ASBMB）赞助的独特国际会议，并题为“脂质生物学领域”。这次会议将召集将介绍，交流和传播其研究并探索未来合作的科学家。会议由ASBMB，脂质生物科学（ICBL）和加拿大脂蛋白会议（CLC）共同组织。与会者的预期人数为250至300。参与者将包括遗传学家，医师科学家，分子生物学家，生物化学家，细胞生物学家，生理学家和结构生物学家，以及来自行业和许多受训者的科学家。该计划将重点介绍脂质生物学的新兴主题，包括脂质代谢的遗传调节，脂肪储存的调节，脂质的细胞生物学，脂质贩运，脂质信号传导，膜动力学以及脂质稳态的损害心脏病，2型糖尿病和肥胖症。 ICBL和CLC各自举行了关于脂质代谢的年度会议，分别参加了52年和35年。重要的是，今年的会议由ASBMB共同赞助，为“特殊研讨会”。因此，这次独特的合并会议将由美国，加拿大和欧洲的科学家组织，并将提供一个独特的机会，将来自不同国际背景的脂质生物学家汇集在一起​​。会议将于2012年9月5日至9日在加拿大班夫的班夫中心举行。该会议将集中于日益认识，即功能失调的脂质代谢是许多人类疾病的发展，例如肥胖，动脉粥样硬化，代谢综合征，肝脏和肺部疾病以及神经退行性疾病。该计划包括7次科学会议，每个会议都会以3或4个演讲，每30分钟，再加上10分钟的讨论。这次会议的一个特别特征是强调研究生，博士后研究员和初级教师的演讲。国际认可的科学家将因其科学卓越而被选中，以及他们清楚和逻辑上介绍他们的工作的能力，将在每个课程中进行谈判。此外，每天3.5个小时将专门用于海报演示，这将为受训者和既定科学家之间的非正式讨论提供一个很好的论坛。该计划和组织委员会包括各种种族的杰出男女科学家。公共卫生相关性：西方世界中最普遍的人类疾病的特征是脂质稳态失调。例如，将过量的脂质储存为脂肪（甘油三酸酯）会导致与肥胖，脂肪肝和2型糖尿病有关的健康问题。过量的血浆胆固醇显着增加了动脉粥样硬化的风险，并且与几种神经退行性疾病（如阿尔茨海默氏病）有关。这个独特的国际会议将解决脂质代谢过程中的当前问题及其与人类疾病的关系。脂质合成，分解和储存的基本过程将在从基本机制到临床意义的研究中进行讨论。因此，这次会议将汇集国际认可的基础科学家和医师科学家，介绍其有关脂质代谢过程损害如何促进诸如动脉粥样硬化，肥胖，2型糖尿病，肝脏和肺病和肺病和神经变性的疾病的发展的最新数据。